NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: VolitionRx's Nu.Q® Cancer Assays Reimbursement Submission in France
TL;DR
VolitionRx's reimbursement submission for Nu.Q Cancer assays in France could provide early market access advantage for lung cancer diagnostics ahead of competitors.
VolitionRx is preparing a reimbursement submission for Nu.Q Cancer assays in France through the Innovative Procedures Outside the Nomenclature framework with Hospices Civils de Lyon support.
VolitionRx's Nu.Q Cancer test aims to improve lung cancer survival rates and identify patients for curative care through earlier detection and monitoring.
VolitionRx's epigenetics approach uses methylated nucleosome biomarkers to provide survival information for non-small cell lung cancer patients at diagnosis.
Found this article helpful?
Share it with your network and spread the knowledge!
VolitionRx Ltd. is preparing a reimbursement submission for its Nu.Q® Cancer assays to government agencies in France, supported by Hospices Civils de Lyon, France's second-largest university hospital system.
The Nu.Q® Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France, specifically for non-small cell lung cancer.
The test measures methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis, which can provide information related to survival and disease progression.
The approach may help identify patients who could benefit from curative care, potentially prolonging life and improving quality of life through earlier detection and monitoring.
The reimbursement submission is expected to be filed under France's 'Innovative Procedures Outside the Nomenclature' framework, which allows early reimbursement support for innovative medical procedures.
Reimbursement would represent a major milestone toward routine clinical use of Nu.Q® Cancer assays in France and support broader commercialization and potential licensing discussions in other markets.
Hospices Civils de Lyon (HCL), France's second-largest university hospital system, is actively supporting the reimbursement submission and running it in parallel with the clinical certification process at HCL.
VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes through earlier detection, disease monitoring, and treatment monitoring.
For further information, visit the company's website at www.Volition.com or view the full press release at https://ibn.fm/qxNIy.
Curated from InvestorBrandNetwork (IBN)
